Biogen Growth Continues, But Analysts Worry About Near-Term R&D Prospects

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

The biotech’s MS franchise led by Tecfidera grew strongly, while SMA therapy Spinraza dipped slightly, but Biogen maintains optimistic outlook amidst growing competition.

Businessman covering his face using a white paper with drawn question mark, like a mask, for hiding his identity. Isolated gray wall background.

Biogen Inc. had a lot of positive news to share with investors during its second quarter earnings call on 23 July, but longer-term questions remain about Spinraza’s fate against growing competition in spinal muscular atrophy, Tecfidera’s standing in multiple sclerosis and the company’s apparent intent to continue pursuing the amyloid beta hypothesis in Alzheimer’s disease.

Overall, the financial picture looked solid in the second quarter – Biogen posted 8% year-over-year revenue growth, about $3.6bn, with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.